2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: Developed by the task force for cardiovascular …
S Halvorsen, J Mehilli, S Cassese, TS Hall… - European heart …, 2022 - academic.oup.com
Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …
evidence shows that it can be considered medically appropriate to a given condition and if …
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
NA ElSayed, G Aleppo, VR Aroda, RR Bannuru… - Diabetes …, 2023 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …
ADA's current clinical practice recommendations and is intended to provide the components …
[HTML][HTML] Pathophysiology of atherosclerosis
S Jebari-Benslaiman, U Galicia-García… - International journal of …, 2022 - mdpi.com
Atherosclerosis is the main risk factor for cardiovascular disease (CVD), which is the leading
cause of mortality worldwide. Atherosclerosis is initiated by endothelium activation and …
cause of mortality worldwide. Atherosclerosis is initiated by endothelium activation and …
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of …
F Mach, C Baigent, AL Catapano… - European heart …, 2020 - academic.oup.com
version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …
[HTML][HTML] Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017 …
SL James, D Abate, KH Abate, SM Abay, C Abbafati… - The Lancet, 2018 - thelancet.com
Summary Background The Global Burden of Diseases, Injuries, and Risk Factors Study
2017 (GBD 2017) includes a comprehensive assessment of incidence, prevalence, and …
2017 (GBD 2017) includes a comprehensive assessment of incidence, prevalence, and …
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group
Summary In 2018, the US National Institute on Aging and the Alzheimer's Association
proposed a purely biological definition of Alzheimer's disease that relies on biomarkers …
proposed a purely biological definition of Alzheimer's disease that relies on biomarkers …
[HTML][HTML] Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic …
T Vos, AA Abajobir, KH Abate, C Abbafati, KM Abbas… - The Lancet, 2017 - thelancet.com
Background As mortality rates decline, life expectancy increases, and populations age, non-
fatal outcomes of diseases and injuries are becoming a larger component of the global …
fatal outcomes of diseases and injuries are becoming a larger component of the global …
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of …
Authors/Task Force Members, SG Priori… - Ep …, 2015 - academic.oup.com
The present document has been conceived as the European update to the American
College of Cardiology (ACC)/American Heart Association (AHA)/ESC 2006 Guidelines for …
College of Cardiology (ACC)/American Heart Association (AHA)/ESC 2006 Guidelines for …
Ezetimibe added to statin therapy after acute coronary syndromes
CP Cannon, MA Blazing, RP Giugliano… - … England Journal of …, 2015 - Mass Medical Soc
Background Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the
risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that …
risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that …
[HTML][HTML] Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes
A Rawshani, A Rawshani, S Franzén… - New England journal …, 2018 - Mass Medical Soc
Background Patients with diabetes are at higher risk for death and cardiovascular outcomes
than the general population. We investigated whether the excess risk of death and …
than the general population. We investigated whether the excess risk of death and …